A newly erected Women’s Health Division within NIH will work in tandem with the Office of Research on Women’s Health.
News|Expert Interviews|September 8, 2020
REDUCE-IT Trial Data Updates: Key Takeaways
A discussion on recent data updates from the REDUCE-IT trial, and their practical implications for physicians managing cardiovascular risk.
Advertisement
A discussion on recent data updates from the REDUCE-IT trial, and their practical implications for physicians managing cardiovascular risk.
Advertisement
Related to this article
Rita King, CEO of MethodSense, provides her expertise on the integration of AI in medical devices and key developments for pharmacists as the technology evolves.
Harini Bupathi, Esq, explains why pharmacies need to continue prioritizing PBM relationships despite rapid legislative change.
Researchers assessed the extent of which vaccine fatigue translates to reduced engagement and adherence among patients.
Brianne Porter, PharmD, MS, explores how pharmacists can deliver care to a population of women experiencing life-altering symptoms of urinary incontinence.
AJ Barbarito, Esq, explains how ERISA and Medicare Part D preemption limit state PBM laws and why a private right of action may be the most effective path forward.
Approval was given to GSK, making its product the first antisense oligonucleotide established for the treatment of chronic hepatitis B.
With safety and efficacy profiles aligning with its brand-name formulation, this new patch could be key for women struggling with hormone therapy adherence.
Advertisement
Advertisement
Trending on Drug Topics
1
PBM Underpayment Persists as Cost-Plus Brings New Strain | NCPA 2026
2
Pharmacist Roles, Risks in Guiding AI-Enabled Medical Device Use
3
Q&A: Why Enforcement Is the Weak Link in State PBM Reform | NCPA 2026
4
FDA Approves Bepirovirsen Injection to Treat Chronic Hepatitis B
5